Granules India Limited (GRANULES.BO)
INR 600.35
(0.58%)
INR 600.35
(0.58%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.15 Billion INR | 15.74% |
| 2022 | 11.36 Billion INR | 2.7% |
| 2021 | 11.06 Billion INR | 30.28% |
| 2020 | 8.49 Billion INR | -4.81% |
| 2019 | 8.92 Billion INR | -10.0% |
| 2018 | 9.91 Billion INR | 0.16% |
| 2017 | 9.89 Billion INR | 50.74% |
| 2016 | 6.56 Billion INR | 13.77% |
| 2015 | 5.77 Billion INR | 0.53% |
| 2014 | 5.74 Billion INR | 29.95% |
| 2013 | 4.41 Billion INR | 63.31% |
| 2012 | 2.7 Billion INR | 32.84% |
| 2011 | 2.03 Billion INR | 48.36% |
| 2010 | 1.37 Billion INR | -6.45% |
| 2009 | 1.46 Billion INR | -19.99% |
| 2008 | 1.83 Billion INR | 26.71% |
| 2007 | 1.44 Billion INR | 8.28% |
| 2006 | 1.33 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 13.15 Billion INR | 15.74% |
| 2023 Q4 | 13.15 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 13.79 Billion INR | 0.0% |
| 2022 FY | 11.36 Billion INR | 2.7% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 11.36 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 10.77 Billion INR | 0.0% |
| 2021 Q2 | 9.75 Billion INR | 0.0% |
| 2021 Q4 | 11.06 Billion INR | 0.0% |
| 2021 FY | 11.06 Billion INR | 30.28% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q4 | 8.49 Billion INR | 0.0% |
| 2020 FY | 8.49 Billion INR | -4.81% |
| 2020 Q2 | 7.71 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 8.92 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 8.39 Billion INR | 0.0% |
| 2019 FY | 8.92 Billion INR | -10.0% |
| 2018 Q4 | 9.91 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 10.97 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 9.91 Billion INR | 0.16% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 7.63 Billion INR | 0.0% |
| 2017 Q4 | 9.89 Billion INR | 0.0% |
| 2017 FY | 9.89 Billion INR | 50.74% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 6.56 Billion INR | 0.0% |
| 2016 FY | 6.56 Billion INR | 13.77% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 5.57 Billion INR | 0.0% |
| 2015 Q2 | 3.93 Billion INR | 0.0% |
| 2015 Q4 | 5.77 Billion INR | 0.0% |
| 2015 FY | 5.77 Billion INR | 0.53% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 4.44 Billion INR | 0.0% |
| 2014 FY | 5.74 Billion INR | 29.95% |
| 2014 Q4 | 5.74 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.31 Billion INR | 0.0% |
| 2013 FY | 4.41 Billion INR | 63.31% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 4.41 Billion INR | 0.0% |
| 2012 Q2 | 1.73 Billion INR | 0.0% |
| 2012 Q4 | 2.7 Billion INR | 0.0% |
| 2012 FY | 2.7 Billion INR | 32.84% |
| 2011 FY | 2.03 Billion INR | 48.36% |
| 2010 FY | 1.37 Billion INR | -6.45% |
| 2009 FY | 1.46 Billion INR | -19.99% |
| 2008 FY | 1.83 Billion INR | 26.71% |
| 2007 FY | 1.44 Billion INR | 8.28% |
| 2006 FY | 1.33 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -3627.506% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -75990.031% |
| Sigachi Industries Limited | 1.43 Billion INR | -819.293% |
| Bal Pharma Limited | 1.39 Billion INR | -841.696% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -7811.777% |
| Medico Remedies Limited | 80.5 Million INR | -16235.387% |
| Lasa Supergenerics Limited | 220.76 Million INR | -5856.931% |
| Venus Remedies Limited | 413.3 Million INR | -3081.863% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -2050.554% |
| Alpa Laboratories Limited | 52.46 Million INR | -24965.548% |
| Nectar Lifesciences Limited | 6.35 Billion INR | -106.922% |
| Shilpa Medicare Limited | 9.37 Billion INR | -40.29% |
| Aarti Drugs Limited | 5.64 Billion INR | -133.056% |
| Lupin Limited | 29.21 Billion INR | 54.991% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 80.218% |
| Zydus Lifesciences Limited | 8.04 Billion INR | -63.524% |
| Windlas Biotech Limited | 36.41 Million INR | -36018.209% |
| Suven Life Sciences Limited | 7.09 Million INR | -185198.577% |
| Eris Lifesciences Limited | 27.81 Billion INR | 52.717% |
| Valiant Laboratories Limited | 767.08 Million INR | -1614.368% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -248.214% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | -30.011% |
| Ipca Laboratories Limited | 14.38 Billion INR | 8.572% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -1217.17% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 59.829% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -295.123% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | -534.768% |
| Laurus Labs Limited | 25.77 Billion INR | 48.977% |
| Piramal Pharma Limited | 47.1 Billion INR | 72.08% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -1714.217% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 67.303% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -156.268% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | -6.835% |
| Unichem Laboratories Limited | 2.47 Billion INR | -431.309% |
| Sequent Scientific Limited | 4.87 Billion INR | -169.65% |
| Novartis India Limited | 69.7 Million INR | -18767.489% |
| Wanbury Limited | 1.16 Billion INR | -1028.96% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -1923.287% |
| Wockhardt Limited | 23.56 Billion INR | 44.182% |
| Themis Medicare Limited | 957.92 Million INR | -1272.83% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -14608.243% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 64.109% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -7568.906% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 34.312% |
| Divi's Laboratories Limited | 30 Million INR | -43735.467% |
| NATCO Pharma Limited | 3.71 Billion INR | -254.274% |
| Gufic Biosciences Limited | 3.32 Billion INR | -295.014% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -3914.237% |
| Ind-Swift Limited | 10.13 Billion INR | -29.691% |
| Procter & Gamble Health Limited | 95.6 Million INR | -13655.9% |
| FDC Limited | 205.18 Million INR | -6309.162% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -579.867% |
| Medicamen Biotech Limited | 308.17 Million INR | -4167.305% |
| Alkem Laboratories Limited | 14.18 Billion INR | 7.286% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -28499.539% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -299527.25% |
| Brooks Laboratories Limited | 56.41 Million INR | -23208.885% |
| Megasoft Limited | 1.47 Billion INR | -794.315% |
| ZIM Laboratories Limited | 1.08 Billion INR | -1108.428% |
| Strides Pharma Science Limited | 25.16 Billion INR | 47.75% |
| Neuland Laboratories Limited | 953.89 Million INR | -1278.624% |
| Morepen Laboratories Limited | 289.99 Million INR | -4434.829% |
| Hikal Limited | 8.17 Billion INR | -60.848% |
| Indoco Remedies Limited | 6.71 Billion INR | -95.706% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -361.022% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -4055.48% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -1235.192% |
| Hester Biosciences Limited | 2.44 Billion INR | -438.127% |